Highly Sensitive Electrochemical Biosensor Using Folic Acid-Modified Reduced Graphene Oxide for the Detection of Cancer Biomarker

• Published in: Nanomaterials (Basel, Switzerland) Vol. 11; no. 5; p. 1272
• Main Authors: Geetha Bai, Renu, Muthoosamy, Kasturi, Tuvikene, Rando, Nay Ming, Huang, Manickam, Sivakumar
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 12.05.2021; MDPI
• Subjects: Arthritis; Biocompatibility; Biomarkers; Biomolecules; Biosensors; Body fluids; Cancer; cancer biomarker; Carbon; Chemical sensors; Drug delivery; Electrochemical analysis; electrochemical sensor; Electrochemistry; Electrodes; folate receptor; folate targeted; Folic acid; Glassy carbon; Graphene; Leukemia; Medical treatment; Metabolism; Nanocomposites; Nanomaterials; Nanoparticles; Nanotechnology; Ovarian cancer; Proteins; rGO-FA; Sensors; Tumors; Vitamin B; United States > US
• ISSN: 2079-4991; 2079-4991
• DOI: 10.3390/nano11051272

The detection of cancer biomarkers in the early stages could prevent cancer-related deaths significantly. Nanomaterials combined with biomolecules are extensively used in drug delivery, imaging, and sensing applications by targeting the overexpressed cancer proteins such as folate receptors (FRs) to control the disease by providing earlier treatments. In this investigation, biocompatible reduced graphene oxide (rGO) nanosheets combined with folic acid (FA)-a vitamin with high bioaffinity to FRs-is utilized to develop an electrochemical sensor for cancer detection. To mimic the cancer cell environment, FR-β protein is used to evaluate the response of the rGO-FA sensor. The formation of the rGO-FA nanocomposite was confirmed through various characterization techniques. A glassy carbon (GC) electrode was then modified with the obtained rGO-FA and analyzed via differential pulse voltammetry (DPV) for its specific detection towards FRs. Using the DPV technique, the rGO-FA-modified electrode exhibited a limit of detection (LOD) of 1.69 pM, determined in a linear concentration range from 6 to 100 pM. This excellent electrochemical performance towards FRs detection could provide a significant contribution towards future cancer diagnosis. Moreover, the rGO-FA sensing platform also showed excellent specificity and reliability when tested against similar interfering biomolecules. This rGO-FA sensor offers a great promise to the future medical industry through its highly sensitive detection towards FRs in a fast, reliable, and economical way.